Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed and are posted here as part of a 12-month trial. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the
Comment published in The Lancet, or visit The Lancet´s
FAQ page, and for any feedback please contact
preprints@lancet.com
Efficacy and Safety of Long-Term Universal Salt Iodization on Thyroid Disorders: An Epidemiological Evidence from 31 Provinces of Mainland China
53 Pages
Posted: 10 Jan 2019
See all articles by Yongze LiChina Medical University - Department of Endocrinology and Metabolism; China Medical University - Institute of Endocrinology
Government of the People's Republic of China - Department of Endocrinology
Third Military Medical University - Department of Endocrinology
Dalian University - Department of Endocrinology
Ningxia Medical University - Department of Endocrinology
Nanchang University - Department of Endocrinology and Metabolism
China Medical University - Department of Endocrinology and Metabolism; China Medical University - Institute of Endocrinology
China Medical University - Department of Endocrinology and Metabolism; China Medical University - Institute of Endocrinology
China Medical University - Department of Endocrinology and Metabolism; China Medical University - Institute of Endocrinology
Harbin Medical University - Department of Endocrinology
Hohhot First Hospital - Department of Endocrinology
Central South University - Department of Endocrinology and Metabolism
Nanjing University of Chinese Medicine (NJUCM) - Research Center of Endocrine and Metabolic Diseases
Fujian Medical University - Fujian Institute of Endocrinology
Zhengzhou University - Division of Endocrinology
Guangxi Medical University - Department of Endocrine
Hainan General Hospital - Department of Endocrinology
Xi'an Jiaotong University (XJTU) - Department of Endocrinology
Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Endocrinology
Lanzhou University - Department of Endocrinology
Sichuan University - Department of Endocrinology and Metabolism
Jilin University (JLU) - Department of Endocrinology and Metabolism
Shanghai University of Medicine and Health Sciences - Department of Endocrinology & Rheumatology
Anhui Medical University - Department of Endocrinology
Kunming University of Science and Technology - Department of Endocrinology
Sun Yat-Sen University (SYSU) - Department of Endocrinology and Metabolism
Shanxi Medical University - Department of Endocrinology
People's Hospital of Tibet Autonomous Region - Department of Endocrinology and Metabolism
Qinghai Provincial People's Hospital - Department of Endocrinology
Zhejiang Provincial Center for Disease Control and Prevention
Guizhou Medical University (Guiyang Medical University) - Department of Endocrinology and Metabolism
Hebei Medical University - Department of Endocrinology
Xinjiang Medical University - Department of Endocrinology
Tianjin Medical University - Department of Endocrinology and Metabolism
Shanghai Jiao Tong University (SJTU) - Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases; Shanghai Jiao Tong University (SJTU) - Shanghai Institute of Endocrine and Metabolic Diseases; Shanghai Jiao Tong University (SJTU) - Shanghai Clinical Center for Endocrine and Metabolic Diseases
Government of the People's Republic of China - Department of Endocrinology
Shandong First Medical University - Department of Endocrinology and Metabolism; Shandong Academy of Clinical Medicine - Institute of Endocrinology; Shandong Clinical Medical Center of Endocrinology and Metabolism
China Medical University - Department of Endocrinology and Metabolism
China Medical University - Department of Endocrinology and Metabolism; China Medical University - Institute of Endocrinology
More...
There are 2 versions of this paper
Abstract
Background: The mandatory universal salt iodization (USI) program has been implemented in China for twenty years. Although iodine deficiency disorders are effectively controlled, the dangers of excess iodine have been debated.
Methods: A nationally representative cross-sectional study of 78,470 participants, aged 18 or older, were enrolled from all 31 provincial regions of mainland China. The participants were given a questionnaire and B-mode ultrasonography on the thyroid. Serum concentrations of thyroid hormones, thyroid antibodies and urine iodine concentration (UIC) were measured.
Findings: The median UIC of school-age children was 199·75µg/L. The weighted prevalence of the thyroid disorders in adults were as follows: 0·78% of overt hyperthyroidism, 0·44 % of subclinical hyperthyroidism, 0·53% of Graves’ disease, 1·02% of overt hypothyroidism, 12·93% of subclinical hypothyroidism, 14·19% of autoimmune thyroiditis, 10·19% of positive TPOAb, 9·70% of positive TgAb, 1·17% of goiter and 20·43 % of thyroid nodules. Iodine excess was only associated with higher odds of overt hyperthyroidism and subclinical hypothyroidism, while iodine deficiency was significantly associated with higher odds of most thyroid disorders. In addition, increased iodine intake was significantly associated with elevated serum TSH levels, but was inversely associated with thyroid antibodies and thyroid nodule.
Interpretation: The long-term mandatory USI program is not only effective for iodine deficient disorders but also safe for prevalence of thyroid disorders based on a sufficient iodine status of pre-USI. The risk of iodine deficiency outweighs that of iodine excess.
Funding Statement: Research Fund for Public Welfare from National Health and Family Planning Commission of China.
Declaration of Interests: All authors declare no competing interests.
Ethics Approval Statement: The research protocols were approved by the Medical Ethics Committee of China Medical University. All subjects were provided written informed consent following a thorough explanation of the research procedures.
Keywords: Iodine; Thyroid disorders; Universal salt iodization; China; Prevalence
Suggested Citation:
Suggested Citation
Li, Yongze and Ba, Jianming and Chen, Bing and Du, Jianling and He, Lanjie and Lai, Xiaoyang and Teng, Xiaochun and Teng, Di and Shi, Xiaoguang and Li, Yanbo and Chi, Haiyi and Liao, Eryuan and Liu, Chao and Liu, Libin and Qin, Guijun and Qin, Yingfen and Quan, Huibiao and Shi, Bingyin and Sun, Hui and Tang, Xulei and Tong, Nanwei and Wang, Guixia and Zhang, Jin-an and Wang, Youmin and Xue, Yuanming and Yan, Li and Yang, Jing and Yang, Lihui and Yao, Yongli and Ye, Zhen and Zhang, Qiao and Zhang, Lihui and Zhu, Jun and Zhu, Mei and Ning, Guang and Mu, Yiming and Zhao, Jiajun and Shan, Zhongyan and Teng, Weiping, Efficacy and Safety of Long-Term Universal Salt Iodization on Thyroid Disorders: An Epidemiological Evidence from 31 Provinces of Mainland China (April 1, 2019). Available at SSRN:
https://ssrn.com/abstract=3310617
Download This Paper
